Zusammenfassung
Durch eine trimodale Behandlungsstrategie bestehend aus neoadjuvanter bzw. adjuvanter Chemotherapie, radikaler Operation und ggf. Strahlentherapie kann bei ausgewählten Patienten mit malignen Pleuratumoren (malignes Pleuramesotheliom, Thymome mit pleuraler Aussaat) eine potenziell kurative Therapie verfolgt werden. Das lokale Tumorrezidiv im Thorax limitiert jedoch weiterhin sowohl das Langzeitüberleben als auch die Lebensqualität der betroffenen Patienten. Aus diesem Grund wird zur Verbesserung der lokalen Tumorkontrolle seit einigen Jahren eine zusätzliche intraoperative Chemotherapie durchgeführt. Voraussetzung ist eine möglichst komplette makroskopische Tumorresektion, welche entweder durch eine radikale Pleurektomie oder eine extrapleurale Pneumonektomie erzielt werden kann. In diesem Beitrag werden das Konzept und das perioperative Management dieses additiven Therapiekonzeptes vorgestellt und die internationale Literatur diskutiert.
Abstract
Trimodality treatment including induction and/or adjuvant chemotherapy, surgical resection and in some cases radiotherapy offers a curative intention in selected patients with pleural malignancies (malignant pleural mesothelioma, thymoma with pleural spread). Nevertheless, locoregional tumor recurrence mainly limits the outcome and the quality of life. A few years ago an additional intraoperative chemotherapy perfusion was developed in order to improve local tumor control and prognosis after surgical resection in a multimodality treatment setting. Cytoreductive surgery with the purpose of a macroscopic complete resection could be achieved by radical pleurectomy or extrapleural pneumonectomy. The concept, techniques and perioperative management of this additional treatment option are presented along with a detailed review of the recent literature.
Literatur
Zauderer MG, Krug LM (2011) The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol 12:163–172
Ruffini E, Van Raemdonck D, Detterbeck F et al (2011) Management of thymic tumors: a survey of current practice among members of the European Society of Thoracic Surgeons. J Thorac Oncol 6(3):614–623
Rena O, Mineo TC, Casadio C (2012) Multimodal treatment for stage IVA thymoma: a proposable strategy. Lung Cancer 76(1):89–92
Kaufman AJ, Flores RM (2011) Surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 12(2):201–206
Yang HC, Yoon YS, Kim HK et al (2011) En bloc extended total thymectomy and extrapleural pneumonectomy in Masaoka stage IVA thymomas. J Cardiothorac Surg 6(28):1–5
Richards WG, Zellos L, Bueno R et al (2006) Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 24:1561–1567
Sugarbaker DJ, Flores RM, Jaklitsch MT et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–63
Yellin A, Simansky DA, Paley M, Refaely Y (2001) Hyperthermic pleural perfusion with cisplatin: early clinical experience. Cancer 92:2197–2203
De Bree E, Ruth S van, Baas P et al (2002) Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 121:480–487
Van Ruth S, Baas P, Haas R et al (2003) Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 10:176–182
Rusch V, Saltz L, Venkatraman E et al (1994) A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 12(6):1156–1163
Refaely Y, Simansky DA, Paley M et al (2001) Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg 72:366–370
Ried M, Potzger T, Braune N et al (2012) Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumors: perioperative management and clinical experience. Eur J Cardiothorac Surg (epub ahead of print)
Hofmann HS, Wiebe K (2010) Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion. Chirurg 81(6):557–562
Ried M, Diez C, Neu R, Hofmann HS (2010) The combined technique of cytoreductive and hyperthermic intrathoracic chemotherapy perfusion. Z Herz-Thorax-Gefäßchir 24(5):277–284
Rusch V, Baldini EH, Bueno R et al (2013) The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: Meeting Summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, Mass. J Thorac Cardiovasc Surg (epub ahead of print)
Flores M (2009) Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication. Semin Thorac Cardiovasc Surg 21(2):149–153
Lang-Lazdunski L, Bille A, Lal R et al (2012) Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 7(4):737–743
Bölükbas S, Manegold C, Eberlein M et al (2009) Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. Lung Cancer 71:75–81
Rice D, Rusch V, Pass H et al (2011) Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 6(8):1304–1312
Sugarbaker DJ, Jaklitsch MT, Bueno R et al (2004) Prevention, early detection and management of complications after 328 consecutive extrapleural pneumoectomies. J Thorac Cardiovasc Surg 128:138–146
Lang-Lazdunski L, Bille A, Belcher E et al (2011) Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol 6(10):1746–1752
Bölükbas S, Eberlein M, Schirren J (2012) Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol 7(5):900–905
Bogliolo GV, Lerza R, Bottino GB et al (1991) Regional pharmacokinetic selectivity of intrapleural cisplatin. Eur J Cancer 27:839–842
Rusch VW, Niedzwiecki D, Tao Y et al (1992) Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 10:1001–1006
Ratto GB, Civalleri D, Esposito M et al (1999) Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 117:759–765
Matsuzaki Y, Tomita M, Shimizu T et al (2008) Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma. Ann Thorac Cardiovasc Surg 14:161–165
Tillemann TR, Richards WG, Zellos L et al (2009) Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 138(2):405–411
Sugarbaker DJ, Bueno R, Krasna MJ et al (2009) Adult chest surgery. Mcgraw-Hill Professional, 1. Aufl.
Zellos L, Richards WG, Capalbo L et al (2009) A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant mesothelioma. J Thorac Cardiovasc Surg 137(2):453–458
Flores RM, Pass HI, Seshan VE et al (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135(3):620–626
Yellin A, Simansky DA, Ben-Avi R et al (2013) Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disease and pleural spread: a single-institution experience. J Thorac Cardiovasc Surg 145(1):83–89
Ried M, Potzger T, Braune N et al (2013) Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies. J Surg Oncol (epub ahead of print)
Sugarbaker DJ, Gill RR, Yeap BY et al (2013) Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg (epub ahead of print)
Cameron RB, Hou D (2012) Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation. J Thorac Cardiovasc Surg 145(2):496–504
Greillier L, Monjanel-Mouterde S, Fraticelli A et al (2009) Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. J Thorac Oncol 4(3):404–408
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seinen Koautor an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ried, M., Hofmann, HS. Intraoperative Chemotherapie nach radikaler Pleurektomie oder extrapleuraler Pneumonektomie. Chirurg 84, 492–496 (2013). https://doi.org/10.1007/s00104-012-2433-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00104-012-2433-4
Schlüsselwörter
- Intraoperative Chemotherapie
- Radikale Pleurektomie
- Extrapleurale Pneumonektomie
- Pleuramesotheliom
- Thymom